Crescent Biopharma
CBIO
87 hedge funds and large institutions have $152M invested in Crescent Biopharma in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
68% more capital invested
Capital invested by funds: $90.4M → $152M (+$61.4M)
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
56% more call options, than puts
Call options by funds: $475K | Put options by funds: $305K
14% more funds holding
Funds holding: 76 → 87 (+11)
0.02% more ownership
Funds ownership: 0.91% → 0.93% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.35M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$1.15M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$743K |
| 4 |
Renaissance Technologies
New York
|
+$731K |
| 5 |
D.E. Shaw & Co
New York
|
+$583K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.65M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$1.42M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$774K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$578K |
| 5 |
Walleye Capital
New York
|
-$407K |
CBIO Hedge Fund Activity: Q2 2020 in Review
87 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2020, worth a combined $152M — up 68% from $90.4M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CBIO positions and 13 closed out — a net gain of 11 holders — while 33 added to existing stakes and 21 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $5.35M. The largest seller was Invesco, cutting an estimated $6.65M.
- 87 institutional investors held Crescent Biopharma (CBIO) as of Q2 2020, up from 76 in Q1 2020.
- Funds reported $152M of Crescent Biopharma stock for Q2 2020, up 68% quarter-over-quarter.
- 24 funds opened new Crescent Biopharma positions in Q2 2020 and 13 closed out, a net change of +11 holders.
- The largest Crescent Biopharma buyer in Q2 2020 was EcoR1 Capital, an estimated $5.35M added.
- The largest Crescent Biopharma seller in Q2 2020 was Invesco, an estimated $6.65M sold.
Based on aggregated 13F filings for Q2 2020.